Ex-Fund Manager Regrets Missing The Boat On A Stock Which Rallied 16% This Week: 'I Should Have Followed My Instincts'
Portfolio Pulse from Shanthi Rexaline
Former hedge fund manager Whitney Tilson expressed regret for not investing in Eli Lilly & Co. (LLY) which saw a 16% rally this week due to strong quarterly results and positive clinical readout from Novo Nordisk A/S (NVO). Tilson had previously highlighted the potential of Lilly's weight-loss drug Mounjaro but decided to stay on the sidelines. He now believes that the positive results from Novo Nordisk's weight-loss drug Wegovy will likely increase the usage of these drugs and expects similar results for Mounjaro.
August 11, 2023 | 9:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's stock rallied 16% this week due to strong quarterly results and positive clinical readout from Novo Nordisk. The company's weight-loss drug Mounjaro is expected to show similar positive results.
The strong quarterly results and positive clinical readout from Novo Nordisk have boosted Eli Lilly's stock. The positive outlook for the company's weight-loss drug Mounjaro also adds to the bullish sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Novo Nordisk's positive clinical results for its weight-loss drug Wegovy is expected to increase the usage of these drugs. This could potentially benefit the company in the long run.
The positive clinical results for Novo Nordisk's weight-loss drug Wegovy is a positive development for the company. This could potentially increase the usage of these drugs and benefit the company in the long run.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80